- Home
- GWRS vs SCPH Comparison
GWRS vs SCPH Comparison
Compare GWRS & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- SCPH
- Stock Information
- Founded
- GWRS 2003
- SCPH 2013
- Country
- GWRS United States
- SCPH United States
- Employees
- GWRS N/A
- SCPH N/A
- Industry
- GWRS Water Supply
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- GWRS Utilities
- SCPH Health Care
- Exchange
- GWRS Nasdaq
- SCPH Nasdaq
- Market Cap
- GWRS 265.4M
- SCPH 299.0M
- IPO Year
- GWRS 2010
- SCPH 2017
- Fundamental
- Price
- GWRS $10.03
- SCPH $5.62
- Analyst Decision
- GWRS
- SCPH Buy
- Analyst Count
- GWRS 0
- SCPH 3
- Target Price
- GWRS N/A
- SCPH $12.00
- AVG Volume (30 Days)
- GWRS 42.0K
- SCPH 2.5M
- Earning Date
- GWRS 11-05-2025
- SCPH 11-12-2025
- Dividend Yield
- GWRS 3.03%
- SCPH N/A
- EPS Growth
- GWRS N/A
- SCPH N/A
- EPS
- GWRS 0.22
- SCPH N/A
- Revenue
- GWRS $54,270,000.00
- SCPH $49,969,000.00
- Revenue This Year
- GWRS $8.11
- SCPH $104.30
- Revenue Next Year
- GWRS $6.71
- SCPH $76.06
- P/E Ratio
- GWRS $45.96
- SCPH N/A
- Revenue Growth
- GWRS 4.33
- SCPH 107.79
- 52 Week Low
- GWRS $9.27
- SCPH $1.94
- 52 Week High
- GWRS $13.98
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- GWRS 55.70
- SCPH 63.32
- Support Level
- GWRS $9.68
- SCPH $4.33
- Resistance Level
- GWRS $10.05
- SCPH $5.62
- Average True Range (ATR)
- GWRS 0.23
- SCPH 0.04
- MACD
- GWRS 0.04
- SCPH -0.01
- Stochastic Oscillator
- GWRS 97.44
- SCPH 80.00
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.